Business context and reporting period
The filing is Visualant, Inc.’s Form 10-K for the fiscal year ended September 30, 2014, filed January 13, 2015. Although the request metadata names USBC, Inc. and “2014 Q4,” the filing identifies Visualant, Inc. as the registrant and reports full-year results; it does not provide a standalone fourth-quarter income statement.
Visualant combined its ChromaID light-based material identification technology with TransTech Systems, a distributor of identification, authentication, access-control and related products. TransTech generated most revenue; ChromaID commercialization was at an early stage. The company reported seven U.S. patents at fiscal year-end, with another patent issued in November 2014.
Financial performance and position
- Revenue: $7.983 million, down 6.9% from $8.573 million in fiscal 2013.
- Gross profit and margin: $1.289 million and 16.1%, versus $1.856 million and 21.6% in 2013. The filing attributes the decline chiefly to $667,000 less Sumitomo license revenue; TransTech’s margin improved from 15.0% to 16.1%.
- Operating expenses: Research and development was $671,000, down from $1.169 million; selling, general and administrative expense was $3.180 million, down from $4.581 million. Operating loss narrowed to $2.561 million from $3.894 million.
- Net loss: $1.017 million, or $0.01 per share, compared with $6.605 million, or $0.05 per share, in 2013. The 2014 result included a $1.605 million noncash gain from changes in warrant derivative fair value; the improvement does not by itself indicate improved operating profitability.
- Cash flow: Cash used in operations was $1.379 million; investing activities provided $29,000 and financing activities provided $673,000. Cash fell to $70,386 from $747,129. A financial-statement note gives operating cash use as $1.404 million, so the filing contains inconsistent values.
- Liquidity and debt: Management reported a $2.697 million working-capital deficit excluding the $2.579 million warrant derivative liability. Current liabilities totaled $6.630 million against current assets of $1.353 million. Current debt was $1.291 million, including a $488,398 receivables credit-line balance, $600,000 in CEO-affiliated notes and a $200,000 Umpqua Bank note. Separately, $166,500 of KBM convertible notes was reported in current liabilities.
- Balance sheet: Total assets were $3.221 million, stockholders’ deficit was $3.409 million, and accumulated deficit was $21.535 million at September 30, 2014.
Material changes versus the prior year
- Revenue fell as the Sumitomo license revenue recognized in 2013 was no longer repeated; TransTech sales increased $69,000 and initial ChromaID shipments contributed $8,000.
- Operating loss improved mainly through lower R&D and SG&A costs, while gross profit declined. TransTech’s operating loss narrowed to $64,000 from $406,000.
- Net loss narrowed substantially, but the comparison was affected by warrant accounting: 2014 included a derivative-liability gain, while 2013 included derivative and warrant-related losses.
- Cash and working capital weakened, and the company relied on new borrowings, including related-party financing, to fund operations.
- TransTech sold its 51% controlling interest in IDVAL on September 30, 2014 for $25,000; the filing reports a $25,065 gain.
Outlook, risks and unusual items
- Management expected continued losses while commercializing ChromaID and said additional financing was necessary to fund operations and service debt. It warned that inability to raise funds could require restructuring or divestitures. The auditor’s report includes a going-concern explanatory paragraph citing substantial doubt about the company’s ability to continue as a going concern.
- No quantified revenue or earnings guidance is provided. Management expects ChromaID to become a major future revenue source through products, licenses, royalties and services, but commercial adoption and additional licensing remain uncertain. The Sumitomo joint development agreement expired December 31, 2013.
- CEO-affiliated lenders provided substantial financing. Several $200,000 and $300,000 demand notes were extended after year-end to March 31, 2015; failure to repay or convert them could trigger a second lien on company assets. The Umpqua note was extended to December 31, 2015. The TransTech credit facility was renewed for six months after year-end; its $488,398 balance was due at facility expiry unless renewed.
- KBM notes totaling $166,500 bear 8% interest and include conversion pricing at 65% of a specified recent low-price average; conversion was unavailable until the second fiscal quarter of 2015. The filing also reports a related derivative liability.
- Potential dilution is substantial: as of September 30, 2014, 168.2 million common shares were outstanding, with 13.1 million options and 128.6 million warrants outstanding, plus potential conversion shares. Warrant down-round provisions can reduce exercise prices. Subsequent to year-end, the company sold $300,000 of Series A preferred stock convertible into 3 million common shares and issued additional warrants.
- Management concluded disclosure controls and internal control over financial reporting were ineffective, citing the absence of an audit committee financial expert. The filing also notes a prior omission of a required advisory compensation vote. Management said it planned governance and compliance remediation.
- Potential regulatory approval may be needed for future medical or other regulated ChromaID applications. TransTech depends on four major vendors for approximately 70% of its revenue. The company also cited IP-protection, financing, share-price volatility and key-personnel risks.
- The filing reports no pending legal proceedings expected to have a material adverse effect. The financial statements received an unqualified audit opinion, subject to the going-concern explanatory paragraph; the auditor did not audit internal-control effectiveness.
Important facts for investors to verify
- Confirm the registrant and period: this is Visualant’s fiscal 2014 annual report, not a USBC filing or a standalone Q4 report.
- Reconcile the $1.379 million versus $1.404 million operating cash-use figures and verify current liquidity, debt maturities and subsequent extensions.
- Assess near-term funding needs and the company’s ability to repay or refinance related-party notes, the receivables line and KBM notes.
- Separate operating performance from the $1.605 million noncash warrant remeasurement gain; verify the derivative-liability accounting and any resulting cash implications.
- Review the fully diluted share count, warrant reset terms, convertible-note pricing and subsequent preferred-stock and warrant issuance for dilution risk.
- Seek evidence of ChromaID customer adoption, licensing or royalty revenue, and confirm progress on internal-control and governance remediation.